UMIN-CTR Clinical Trial

UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials


Recruitment status Completed
Unique ID issued by UMIN UMIN000042009
Receipt No. R000047366
Scientific Title A multicenter randomized controlled trial for evaluated the efficacy and safety of TDM-621
Date of disclosure of the study information 2020/10/05
Last modified on 2020/10/05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments

Basic information
Public title TDM-621 clinical trial
Acronym TDM-621 clinical trial
Scientific Title A multicenter randomized controlled trial for evaluated the efficacy and safety of TDM-621
Scientific Title:Acronym TDM-621 clinical trial

Condition Patients undergoing ESD for neoplasia of the stomach and rectum
Classification by specialty
Classification by malignancy Malignancy
Genomic information NO

Narrative objectives1 evaluated the efficacy and safety of TDM-621 during ESD
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Primary outcomes the number of coagulation by hemostatic forceps required to achieve intraprocedural haemostasis in TDM-621 versus control groups.
Key secondary outcomes

Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Cluster
Blinding Open -no one is blinded
Control Active
Stratification YES
Dynamic allocation YES
Institution consideration Institution is considered as adjustment factor in dynamic allocation.
Blocking NO

No. of arms 2
Purpose of intervention Treatment
Type of intervention
Interventions/Control_1 TDM-621
Interventions/Control_2 Control(Hemostatic forceps)

Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Subjects who met all of the following items at the time of registration were included in this clinical trial.
(1) An epithelial tumor with a maximum diameter of 3 cm to 6 cm (which is a single lesion) that is expected to be resected specimen for which ESD of the stomach (upper, middle) or rectum (upper, lower) is indicated Patients with
(Based on the guidelines for gastric cancer/colon cancer treatment and stomach/colon ESD/EMR guidelines)
Stomach: A differentiated cancer that is macroscopically diagnosed as intramucosal cancer (T1a) and is UL (-).
Rectum: Preoperatively diagnosed with adenoma, intramucosal cancer, or mild invasive cancer in the submucosa
(2) Patients aged 20 years or older at the time of obtaining consent
(3) Patients who understand the content of the consent explanation document and can freely consent to the document
(4) Patients who can visit the hospital and can be examined on a designated examination date such as examination schedule
(5) Patients who are hospitalized or will be hospitalized
Key exclusion criteria Subjects who met any of the following items at the time of enrollment were excluded from this trial.
(1) Patients with local residual recurrence
(2) Patients with ulcer in the target lesion
(3) Poorly differentiated adenocarcinoma or undifferentiated cancer gastric cancer patients and rectal cancer patients
(4) Patients with inflammatory bowel disease including ulcerative colitis
(5) Patients with a history of hypersensitivity to peptide or protein products
(6) Patients with Grade 2 or higher of Performance status according to the clinical evaluation criteria of cancer chemotherapy
(7) Patients with serious liver disease, renal disease, cardiovascular disease, etc. [Assessment of severity of adverse event grade 3 or more in the Common Terminology Criteria for Adverse Events]
(8) Patients with a condition in which reticuloendothelial system activity may be decreased such as disseminated intravascular coagulation
(9) Patients who are receiving blood coagulation drugs (coagulation promoter = hemocoagulase, etc.), antifibrinolytic drugs (drugs having antifibrinolytic action = tranexamic acid, aprotinin preparation, etc.). However, regardless of the use of antiplatelet drugs, the drug should be discontinued in accordance with the guideline for gastrointestinal endoscopy for patients taking antithrombotic drugs.
(10) Patients who are scheduled to undergo heparin replacement for ESD
Target sample size 170

Research contact person
Name of lead principal investigator
1st name satoru
Middle name
Last name kobayashi
Organization 3-D Matrix, Ltd.
Division name Business Development
Zip code 1020083
Address kojimachi-HF Building 7F 3-2-4, chiyoda-ku, Tokyo, Japan
TEL 0335113440

Public contact
Name of contact person
1st name Yoshitaka
Middle name
Last name Kanemitsu
Organization 3D-Matrix, Ltd
Division name Business Development
Zip code 1020083
Address kojimachi-HF Building 7F 3-2-4, chiyoda-ku, Tokyo, Japan
TEL 0335113440
Homepage URL

Institute 3-D Matrix, Ltd.

Funding Source
Organization 3-D Matrix, Ltd.
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Name of secondary funder(s)

IRB Contact (For public release)
Organization TDM-621 clinical trial IRB
Address kojimachi-HF Building 7F 3-2-4, chiyoda-ku, Tokyo, Japan
Tel 03-3511-3440

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2


Other administrative information
Date of disclosure of the study information
2020 Year 10 Month 05 Day

Related information
URL releasing protocol
Publication of results Unpublished

URL related to results and publications
Number of participants that the trial has enrolled 227
Results date posted
Results Delayed
Delay expected
Results Delay Reason under reviewing
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Recruitment status Completed
Date of protocol fixation
2017 Year 05 Month 11 Day
Date of IRB
2017 Year 06 Month 19 Day
Anticipated trial start date
2017 Year 08 Month 03 Day
Last follow-up date
2019 Year 08 Month 14 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other related information

Management information
Registered date
2020 Year 10 Month 05 Day
Last modified on
2020 Year 10 Month 05 Day

Link to view the page

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name

Contact us.